Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Ok'd to Launch PARP Inhibitor in Hong Kong

publication date: Oct 22, 2018

Zai Lab of Shanghai was approved in Hong Kong to market Zejula® (niraparib), an oral, once-daily PARP inhibitor for adult ovarian cancer patients. The approval of Zejula was based on the global Phase III trial of Zejula sponsored by Tesaro. Zai in-licensed China rights (including Hong Kong) to the drug from Tesaro in 2016. It is Zai's first marketing approval, and the company expects to launch Zejula before the end of the year. Zai is continuing to conduct China trials of Zejula. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.